Helius Medical Technologies (Canada) Join Forces With Brainfx to Create Educational Awareness on Innovative Treatment and Assessments in Brain HealthOct 28 2020Helius Medical Technologies, Inc. Announces Publication of Peer-Reviewed Study: Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain InjurySep 08 2020
In the News
As Seen On ...
PoNS™ is an authorized medical device and commercially available in Canada. PoNS™ is an investigational device in the US, EU, and Australia and is currently under review for market clearance by the AUS TGA; PoNS™ is not commercially available in the US, EU, or Australia.
The device is intended for use as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is intended for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy.